Anemia in the elderly – part 2
A major cause of anemia that increases with age is myelodysplastic syndrome (MDS). It is accepted that older people with mild anemia of unknown cause, after a period of observation develop a complete MTO picture. However, despite what was said above, this group remains a proportion of patients with anemia and cannot be interpreted.
For the assessment of the elderly patient with anemia is important to obtain a detailed history, including drugs that are already operating, and the recognition of co-morbidities.
Few specific studies have been done and, therefore, there are no guidelines for the treatment of anemia in the elderly, despite the increased impact. The therapeutic approach to anemia in the elderly should be explanatory and includes, besides the reduction of anemia, treatment of the disease responsible.
Thus, the iron deficiency is the most frequent cause, besides iron preparation administration is necessary and finding the cause and treatment of iron deficiency anemia with control of the digestive system for investigation of colon cancer or stomach. The administration of erythropoietin is a treatment of chronic anemia, except of course addressing the responsible disease. In patients with chronic renal failure, administration of erythropoietin has been established for many years. For patients in the third group, with predominantly myelodysplastic syndrome in the initial phase, the administration of erythropoietin can reduce anemia and improve quality of life.
Anemia of the elderly is now recognized as a frequent and important cause of increased morbidity and mortality in this vulnerable population group. Improving public health concerns in the treatment of anemia in the elderly has created many concerns, such as:
- Is there a separate entity known as “anemia of aging”?
- Should all older people to be controlled by routine tests for possible anemia?
- In what percentage the anemia participates on morbidity of the elderly and how can this be corrected with modern treatments?
- What will be the economic impact on health systems of a more aggressive strategy in the treatment of aging anemia?
However, to answer safely the questions above, it is necessary to perform clinical studies that include a large number of elderly patients.
…this article is provided by www.tiptonhomecare.co.uk